MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis - Université de Bretagne Occidentale
Journal Articles Clinical Lung Cancer Year : 2019

MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis

Domains

Life Sciences [q-bio] Immunology

Geneviève Michel  : Connect in order to contact the contributor

https://hal.univ-brest.fr/hal-02262486

Submitted on : Friday, August 2, 2019-3:35:52 PM

Last modification on : Tuesday, July 18, 2023-4:25:40 PM

No file

Dates and versions

hal-02262486 , version 1 (02-08-2019)

Identifiers

Cite

Laetitia Lambros, Arnaud Uguen. MET Immunohistochemistry Should Be Avoided in Selecting Non–small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis. Clinical Lung Cancer, 2019, 20 (3), pp.e418-e420. ⟨10.1016/j.cllc.2018.12.002⟩. ⟨hal-02262486⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-BREST IMMUNO IBSAM
51 View
0 Download

Altmetric

Share

More